The drug was administered subcutaneously using a dose that effectively blocks the cytokine-elicited NF-κB activation in vitro (not shown) and inhibits muscle damage in mouse models of limb-girdle and of Duchenne dystrophies, and of inflammatory idiopathic myopathies [36–39]. This evidence concerns the gene NFKB1 and idiopathic inflammatory myopathy.